Emerging molecular targeted therapies in the treatment of head and neck cancer
- PMID: 19519286
- DOI: 10.1517/14728210902997947
Emerging molecular targeted therapies in the treatment of head and neck cancer
Abstract
Current development of molecular targeted therapies in oncology is particularly active. The aim of this study is to review recent advances in the field of molecular targeted therapies for head and neck squamous cell carcinoma (HNSCC). As EGFR signaling pathway and angiogenesis play a key role in the growth of HNSCC, EGFR with its downstream effectors and molecular factors implicated in the angiogenesis process, such as VEGF and its receptors, represent the main targets of the new therapeutic agents now in development. Today, cetuximab, an anti-EGFR monoclonal antibody, is the only targeted therapy approved for the treatment of HNSCC in patients with locally advanced tumors, in association with radiotherapy, and in patients with recurrent or metastatic diseases. Future progress is expected with the integration of cetuximab into induction chemotherapeutic regimens or in association with concurrent chemoradiotherapy for locally advanced tumors and with the development and evaluation of other molecular targeted therapies such as antiangiogenic drugs. As these innovative molecules start to be used in clinical practice, the identification of predictive markers for efficacy and toxicity becomes a crucial issue.
Similar articles
-
Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.Anticancer Agents Med Chem. 2013 Mar;13(3):389-402. Anticancer Agents Med Chem. 2013. PMID: 23092267 Review.
-
Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.Curr Opin Oncol. 2008 May;20(3):256-63. doi: 10.1097/CCO.0b013e3282f9b575. Curr Opin Oncol. 2008. PMID: 18391623 Review.
-
Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.Curr Opin Oncol. 2006 May;18(3):247-52. doi: 10.1097/01.cco.0000219253.53091.fb. Curr Opin Oncol. 2006. PMID: 16552236 Review.
-
The emerging role of cetuximab in head and neck cancer: a 2007 perspective.Cancer Invest. 2008 Feb;26(1):96-103. doi: 10.1080/07357900701601002. Cancer Invest. 2008. PMID: 18181051 Review.
-
EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.Expert Opin Emerg Drugs. 2010 Jun;15(2):185-201. doi: 10.1517/14728211003716442. Expert Opin Emerg Drugs. 2010. PMID: 20415599 Review.
Cited by
-
Inherent phenotypic plasticity facilitates progression of head and neck cancer: endotheliod characteristics enable angiogenesis and invasion.Exp Cell Res. 2013 Apr 15;319(7):1028-42. doi: 10.1016/j.yexcr.2013.01.013. Epub 2013 Jan 29. Exp Cell Res. 2013. PMID: 23370231 Free PMC article.
-
Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells.PLoS One. 2013;8(1):e54736. doi: 10.1371/journal.pone.0054736. Epub 2013 Jan 23. PLoS One. 2013. PMID: 23372762 Free PMC article.
-
Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli.Bioorg Med Chem. 2010 Jun 1;18(11):3823-33. doi: 10.1016/j.bmc.2010.04.047. Epub 2010 Apr 21. Bioorg Med Chem. 2010. PMID: 20466556 Free PMC article.
-
GSK1059615 kills head and neck squamous cell carcinoma cells possibly via activating mitochondrial programmed necrosis pathway.Oncotarget. 2017 Feb 7;8(31):50814-50823. doi: 10.18632/oncotarget.15135. eCollection 2017 Aug 1. Oncotarget. 2017. PMID: 28881606 Free PMC article.
-
HPV infection related immune infiltration gene associated therapeutic strategy and clinical outcome in HNSCC.BMC Cancer. 2020 Aug 24;20(1):796. doi: 10.1186/s12885-020-07298-y. BMC Cancer. 2020. PMID: 32831060 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
